Samsung Medison, a prominent global medical equipment company and affiliate of Samsung Electronics, has announced the acquisition of 100% of the shares of Sonio SAS, a specialized fetal ultrasound AI software company headquartered in France.

Sonio, founded in 2020, focuses on advancing women's and children's health through innovative medical technologies. The company has made significant strides in obstetrics and gynecology, developing IT solutions and AI assistant features that enhance the evaluation and documentation of ultrasound exams. Among its key products is Sonio Detect, an FDA 510(k) cleared AI assistant that employs deep learning networks to ensure higher image quality in real-time, thereby improving clinical accuracy and the overall quality of care.

Upon completion of the acquisition, Sonio will continue to operate as an independent entity, maintaining its headquarters in France. The company will sustain its commercial growth independently, ensuring that its products and services remain compatible with ultrasound devices from various manufacturers.

The integration of Sonio's advanced AI capabilities with Samsung Medison's state-of-the-art ultrasound systems is expected to foster significant innovations in prenatal care. This collaboration aims to develop AI-enhanced workflows that will advance patient outcomes and elevate the standards of prenatal care globally.

"We have great respect and admiration for what the Sonio team has built in the area of maternal care," stated Yong Kwan Kim, CEO of Samsung Medison. "Through the acquisition of Sonio, Samsung Medison will continue to deliver upon our promise to improve the quality of people’s lives with technology. Collaboration with Sonio will bring together best-in-class ultrasound AI technology and reporting capabilities to bring a paradigm shift in the prenatal ultrasound exam."

Cécile Brosset, CEO of Sonio, expressed enthusiasm for the partnership, stating, "Samsung Medison’s established global ultrasound business combined with Sonio’s advanced AI creates an exciting growth opportunity for both sides. We have found in Samsung Medison an amazing, trusting partner to pursue and accelerate our roadmap and mission. In addition to close collaboration with Samsung Medison, as an independent company, Sonio will continue to advance medical reporting technology and diagnostic software globally, including for underserved areas in healthcare."

The transaction is pending regulatory approvals, including the endorsement of the French Ministry of the Economy and Finance.